- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06906341
Relacorilant in combinatie met NAB-Paclitaxel en bevacizumab in gevorderde, epitheliale eierstok, primaire peritoneale of eileider-buiskanker
Een fase 2-studie van relacorilant in combinatie met NAB-paclitaxel en bevacizumab in geavanceerde, epitheliale eierstok, primaire peritoneale of eileider-buiskanker (Bella)
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
This study is designed with the goal to add additional arms as new treatments become available. All arms will follow an independent and parallel design.
For Arms A and B, study treatment will comprise relacorilant combined with nab-paclitaxel, and bevacizumab and will begin on Cycle 1 Day 1 (C1D1). Each patient will receive relacorilant 150 mg administered orally under fed conditions, once daily for 3 consecutive days on the day before, the day of, and the day after nab-paclitaxel infusion (in Cycle 1 relacorilant is only given on 2 consecutive days, starting on C1D1), in combination with nab-paclitaxel (80 mg/m^2 intravenously [IV]) administered on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab (10 mg/kg IV once every 2 weeks [Q2W]) will be administered on Days 1 and 15 of each 28-day cycle. Study treatment for Arm C will be similar to Arm A but does not include bevacizumab. Patients will receive treatment until they reach a protocol-defined event of progressive disease (PD), experience an unmanageable toxicity, or until other treatment discontinuation criteria are met.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Corcept Therapeutics
- Telefoonnummer: 650-414-2314
- E-mail: corceptstudy557@corcept.com
Studie Locaties
-
-
-
Brussels, België, 1200
- Werving
- 109
-
Charleroi, België, 6000
- Werving
- 326
-
Hasselt, België, 3500
- Werving
- 325
-
Leuven, België, 3000
- Werving
- 108
-
-
Belgium
-
Aalst, Belgium, België, 9300
- Werving
- 328
-
-
-
-
-
Aachen, Duitsland, 52074
- Werving
- 519
-
Berlin, Duitsland, 10117
- Werving
- 255
-
Kempten, Duitsland, 87439
- Werving
- 520
-
-
-
-
-
Lille, Frankrijk, 59000
- Werving
- 306
-
Nancy, Frankrijk, 54100
- Werving
- 307
-
Nice, Frankrijk, 06100
- Werving
- 310
-
Pierre-Bénite, Frankrijk, 69495
- Werving
- 324
-
Plérin, Frankrijk, 22190
- Werving
- 323
-
Toulouse, Frankrijk, 31059
- Werving
- 308
-
-
-
-
-
Catania, Italië, 95126
- Werving
- 321
-
Milan, Italië, 20141
- Werving
- 122
-
Milan, Italië, 20159
- Werving
- 516
-
Pavia, Italië, 27100
- Werving
- 295
-
Rome, Italië, 00168
- Werving
- 124
-
Torino, Italië, 10128
- Werving
- 293
-
Treviso, Italië, 31100
- Werving
- 319
-
-
-
-
-
Gdynia, Polen, 81-519
- Werving
- 341
-
Siedlce, Polen, 08-MO
- Werving
- 329
-
-
-
-
-
Badalona, Spanje, 08916
- Werving
- 349
-
Barcelona, Spanje, 08035
- Werving
- 115
-
Madrid, Spanje, 28034
- Werving
- 114
-
Valencia, Spanje, 46026
- Werving
- 330
-
Valencia, Spanje, 46010
- Werving
- 558
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35233
- Werving
- 004
-
-
California
-
Palo Alto, California, Verenigde Staten, 94304
- Werving
- 150
-
San Francisco, California, Verenigde Staten, 94109
- Werving
- 278
-
San Francisco, California, Verenigde Staten, 94143
- Werving
- 014
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Werving
- 032
-
-
Florida
-
Fort Myers, Florida, Verenigde Staten, 33901
- Werving
- 544
-
Miami Beach, Florida, Verenigde Staten, 33140
- Werving
- 335
-
West Palm Beach, Florida, Verenigde Staten, 33041
- Werving
- 543
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- 001
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55404
- Werving
- 518
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64132
- Werving
- 334
-
St Louis, Missouri, Verenigde Staten, 63110
- Werving
- 521
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 97102
- Werving
- 292
-
-
Ohio
-
Centerville, Ohio, Verenigde Staten, 45459
- Werving
- 304
-
-
Oregon
-
Eugene, Oregon, Verenigde Staten, 97401
- Werving
- 517
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213
- Werving
- 127
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Werving
- 522
-
Norfolk, Virginia, Verenigde Staten, 23502
- Werving
- 300
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Werving
- 121
-
-
-
-
Gangnam-gu
-
Seoul, Gangnam-gu, Zuid -Korea, 06351
- Werving
- 396
-
-
Goyang-si
-
Gyeonggi-do, Goyang-si, Zuid -Korea, 10408
- Werving
- 397
-
-
Jongno-gu
-
Seoul, Jongno-gu, Zuid -Korea, 03080
- Werving
- 399
-
-
Seocho-gu
-
Seoul, Seocho-gu, Zuid -Korea, 06591
- Werving
- 523
-
-
Seodaemun-gu
-
Seoul, Seodaemun-gu, Zuid -Korea, 03722
- Werving
- 398
-
-
Songpa-gu
-
Seoul, Songpa-gu, Zuid -Korea, 05505
- Werving
- 403
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Arms A and B
- Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
- Arm A Only: Platinum-resistant disease
- Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
- Life expectancy of ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Able to swallow and retain oral medication
- 1 to 3 lines of prior systemic anticancer therapy
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Arm C
- Stage III or IV, recurrent, or metastatic endometrial cancer
- Life expectancy of ≥3 months
- ECOG performance status of 0 or 1
- Able to swallow and retain oral medication
- Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
- 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
- Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Exclusion Criteria:
Arm A and B
- Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- Untreated or symptomatic central nervous system metastases
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
Arm C
- Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
- Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A: Relacorilant in Combination with Nab-paclitaxel and Bevacizumab
In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Andere namen:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
Experimenteel: Arm B: Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab
In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Andere namen:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
Experimenteel: Arm C: Relacorilant in Combination with Nab-Paclitaxel
In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Andere namen:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-Free Survival (PFS)
Tijdsspanne: Date of first dose until PD or death, up to 18 months
|
To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first. |
Date of first dose until PD or death, up to 18 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Aantal patiënten met een of meer bijwerkingen
Tijdsspanne: Datum van eerste dosis tot 30 dagen na de laatste dosis
|
Datum van eerste dosis tot 30 dagen na de laatste dosis
|
|
|
Objective Response Rate (ORR)
Tijdsspanne: Date of first dose until PD or death, up to 18 months
|
To evaluate the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST version 1.1. |
Date of first dose until PD or death, up to 18 months
|
|
Best Overall Response Rate (BOR)
Tijdsspanne: Date of first dose until PD or death, up to 18 months
|
To evaluate the BOR by RECIST version 1.1 recorded from the date of enrollment until PD or death. |
Date of first dose until PD or death, up to 18 months
|
|
Duration of Response (DOR)
Tijdsspanne: Time of first objective response until PD or death, up to 18 months
|
To evaluate DOR as the time from the first CR or PR to first objectively documented PD or death, whichever comes first. |
Time of first objective response until PD or death, up to 18 months
|
|
Clinical Benefit Rate (CBR)
Tijdsspanne: Week 24
|
To evaluate CBR as the proportion of patients who attain CR, PR, or stable disease (SD) at Week 24 as per RECIST version 1.1. |
Week 24
|
|
Overall Survival (OS)
Tijdsspanne: Date of first dose up to 6, 12, and 18 months
|
To evaluate the probability of OS survival at 6, 12, and 18 months. |
Date of first dose up to 6, 12, and 18 months
|
|
Area under the plasma concentration-time curve (AUC) of relacorilant
Tijdsspanne: On Cycle 1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 1 Day 8 (each cycle is 28 days)
|
|
Maximum plasma concentration (Cmax) of relacorilant
Tijdsspanne: On Cycle1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle1 Day 8 (each cycle is 28 days)
|
|
Trough plasma concentrations (Cmin) of relacorilant
Tijdsspanne: On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Danny Nguyen, MD, Corcept Therapeutics
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- Neoplasmata
- Bevacizumab
- Ovariumneoplasmata
- Paclitaxel
- Relacorilant
- Nab-paclitaxel
- Ovarieel
- Neoplasmata per site
- Endometrium
- Hoog cijfer
- Eierstokziekten
- Genitale neoplasmata, vrouwelijk
- Peritoneale neoplasmata
- Eileiderneoplasmata
- Platinabestendig
- Endometrium neoplasma
- Ziekten van de eileiders
- Albumine-gebonden paclitaxel
- Peritoneale of gevorderde eileiderige buiskanker
- Bella
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Endocriene systeemziekten
- Urogenitale neoplasmata
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Baarmoeder Ziekten
- Genitale ziekten, vrouw
- Endocriene klierneoplasmata
- Adnexale ziekten
- Gonadale aandoeningen
- Baarmoeder Neoplasmata
- Peritoneale ziekten
- Abdominale neoplasmata
- Neoplasmata
- Ovariumneoplasmata
- Endometriumneoplasmata
- Genitale neoplasmata, vrouwelijk
- Peritoneale neoplasmata
- Eileiderneoplasmata
- Neoplasmata per site
- Ovariële ziekten
- Ziekten van de eileiders
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Bevacizumab
- 130-nm albumine-gebonden Paclitaxel
- relacorilant
Andere studie-ID-nummers
- CORT125134-557
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .